Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. EW has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
EW stock price ended at $76.04 on , after rising1.21%
The Edwards Lifesciences Corp stock price increased by 1.21% on the last trading day (), rising from 74.82 to 76.04. Throughout the last trading session, the stock experienced a fluctuation of 2.70% , ranging from a day low of $74.1 to a day high of 76.1. The price has declined in 2 of the last 10 days, resulting in a total change of 11.40% during this period. On the last day, trading volume decrease by -5.38M shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 6.33M shares were traded, amounting to approximately 478.82M.
EW Technical Signals
EW(Edwards Lifesciences Corp Corp) has buy signals and sell signals now. The average turnover of EW over the last 5 trading days is NaN. Overall, the technical indicator signals lean more toward a outlook in the mid-term.
EW Moving Average Analysis
Edwards Lifesciences Corp's overall moving average trend leans more bullish as of Monday, April 28, 2025, with 1 negative signals and 3 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $, and $. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $, and $. A break-down below any of these levels will issue sell signals.
EW Short Selling Analysis
The short sale ratio of Edwards Lifesciences Corp(EW) as of is %, dropping from last trading day. With decreasing price from to .
Technical Signal
Technical Signals Summary
Sell
Buy
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
Bullish Signals
0 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
No Data
Bearish Signals
0 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
No Data
EW
Name
Similarity
Up/Down
No Data
EW Seasonality Analysis
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Edwards Lifesciences Corp (EW.N) stock in has the highest probability of a positive return (%), while has the lowest probability (%).
Performance Seasonality
The chart shows Edwards Lifesciences Corp. (EW)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Edwards Lifesciences Corp (EW.N) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. EW has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Edwards Lifesciences Corp (EW.N) stock in a year?
The radar chart shows that buying Edwards Lifesciences Corp (EW.N) stock in has the highest probability of a positive return (45.45%), while has the lowest probability (45.45%).
How has Edwards Lifesciences Corp. (EW)'s stock price performed over the past three years?
EW's stock price fell by in Invalid Date,in by
Which bull technical signals does EW have?
Bullish technical signals of EW include:
Which bearish technical signals does EW have?
Bearish technical signals of EW include:
Is EW a buy based on overall technical signals summary?
EW has 6 buy signals and 4 sell signals now. Overall the technical rating for EW is . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of EW.
What is the trend of Edwards Lifesciences Corp (EW)'s moving average?
Edwards Lifesciences Corp's overall moving average trend leans more bullish as of April 28 2025, with 3 negative signals and 1 positive signal.
What is price prediction for EW stock next month?
The price prediction chart for Edwards Lifesciences Corp (EW.N) stock, as of Invalid Date, forecasts a % change over the next month, based on its high correlation with stock patterns. The similarity between their price movements over the analyzed periods is %. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for EW Stock?
The price target for EW stock in 2025 is expected to reach **$75.45**, driven by strong earnings growth, expansion in the TAVR segment, and positive analyst upgrades. The stock is currently trading near its Fibonacci R1 level of $71.61, with upside potential supported by its average analyst price target of $79.11.
What is price prediction 2030 for EW Stock?
### **Price Prediction for EW Stock in 2030**
Based on current trends and analyst sentiment, EW stock is predicted to reach **$85 by 2030**, driven by its strong product pipeline and revenue growth in structural heart disease treatments. The stock is expected to benefit from its leadership in transcatheter heart valve technologies and improving long-term patient outcomes. Analysts maintain a "Moderate Buy" rating with a target price of $79.11, suggesting a potential upside of 13.2% from current levels.